123 results about "Tetanus toxoids" patented technology

A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide on Haemophilus influenzae type b and tetanus toxoid or diphtheria toxoid, which may be reconstituted from a lyophilized state by the other component. The administration of the multiple component vaccine resulted in no diminution of the immunogenicity of any component as a result of interference by other components of the vaccine.

The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and Pseudomonas Exotoxin A, from a bacterial host.

The invention discloses a combined vaccine and a preparation method thereof. The combined vaccine is formed by a component A and a component B, wherein the component A is a liquid preparation and composed of pertussis toxin, filamentous hemagglutinin, pertussis adhesion, diphtheria toxoid, tetanus toxoid, aluminium hydroxide and sodium chloride; the component B is a freeze-drying preparation and composed of A-group meningitis polysaccharide conjugate, C-group meningitis polysaccharide conjugate, b-type haemophilus influenzae polysaccharide conjugate and lactose. The preparation method of the vaccine includes the steps of preparing of acellular pertussis-diphtheria-tetanus vaccine semi-finished products, A-group and C-group meningococcocci and b-type haemophilus influenzae combined vaccine semi-finished products, split charging and packaging. The vaccine has the characteristics of being safe, effective, controllable and capable of preventing diseases through an injection, the preparation method is easy to operate, preparation is facilitated, cost is low, and the combined vaccine is suitable for industrialized mass production.

Processes for preparing combination vaccines that include diphtheria and tetanus toxoids, where these two toxoids are used in the processes as a single component containing both toxoids, and also containing 1-hydroxy-2-phenoxyethane.

Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a tetanus toxoid.

The invention discloses a method for refining a polyvalent ASV (anti-snake venom) lyophilized serum, pertaining to an immune serum containing antibody which aims at least two kinds of antigens. The serum takes the venom of Ancistrodon acutus, Agkistrodon halys, Pit-vipers, bamboo snakes, adders and the like as the immune antigen which is inoculated into the bodies of animals after degerming and dialysis, and then titer immune serum after purification is used for collecting the antibody which is then desalted and lyophilized; mice are used for evaluating the LD50 of the virulence of the venom and the titer of the ASV serum; the antibody inoculated into the bodies of the animals is one of the venom, toxoid or snake venom or the composition thereof, and glutaraldehyde or formaldehyde is used for toxin detoxication; before immunity, anti-tetanic toxoid condensed antibody for human beings is used for carrying out minim gradual immunization on the animals, or an Emuade adjuvant is used for immunization purpose. The polyvalent ASV lyophilized serum complies with the biological product standards upon the tests and inspections of purity and specific activity, safety, pyrogen, hypersusceptibility, dissolution and the like; moreover, the serum can cure sufferers who are bitten by vipers with the advantages of high purity, low foreign protein, easy preservation and quick dissolving capacity.

The invention relates to a tetanus toxoid monoclonal antibody and a preparation method and application thereof, in particular to a tetanus toxoid monoclonal antibody. A complementary determining region (CDR) of a heavy chain variable region of the monoclonal antibody comprises CDR1 shown as SEQ ID NO:6, CDR2 shown as SEQ ID NO:8 and/or CDR3 shown as SEQ ID NO:10; and a CDR of a light chain variable region of the monoclonal antibody comprises CDR1 shown as SEQ ID NO:12, CDR2 shown as SEQ ID NO:14 and CDR3 shown as SEQ ID NO:16. The invention also provides a deoxyribonucleic acid (DNA) moleculefor coding the sequence, an expression vector and a host cell.

The invention provides a rabies vaccine for human beings, which contains an outer membrane fragment of a split rabies virus particle and tetanus toxoid; the outer membrane fragment comprises furcella and matrix protein, wherein each dosage of rabies vaccine for human beings contains 10-150 micrograms of virus protein; and the dosage of the tetanus toxoid is 3-10 Lf/dosage. Compared with the existing virus purification stock solution, the rabies vaccine for human beings contains less other proteins, has higher immunogenicity and effect, and is more secure for use.

The invention discloses an optimization method of Haemophilus Influenzae Serotype B polysaccharide and protein binding process, and the method comprises the following steps of: derivating polysaccharide, and preparing polysaccharide-TT (tetanus toxoid) conjugate. The invention provides a novel bridging substance combined by polysaccharide and vector protein, and the novel bridging substance can be used for more effectively performing binding reaction by changing a bridge molecule based on a conventional method, so that the binding rate of polysaccharide and vector protein is improved, the binding reaction time is shortened, the yield of qualified conjugate of the binding reaction is improved to a certain extent, the binding reaction has high repeatability, large-scale production is facilitated, and the production cost is reduced.

The invention provides a multivalent immunogenic composition containing enterovirus antigens. The composition comprises inactivated EV71 antigens and/or inactivated CA16 antigens, and inactivated polio antigens. The composition can further comprise antigens selected from hepatitis A antigens, hepatitis B antigens, acellular pertussis antigens, tetanus toxoid, diphtheria toxoid, Haemophilus influenzae type b capsular polysaccharide, and meningococcal polysaccharide antigens, as well as physiologically acceptable carriers combined with bacterial polysaccharide antigens. The invention also provides a preparation method of the composition. The composition can prevent invasion of a plurality of pathogens simultaneously without interference among the antigens, and the immunogenicity is no less than that of individually activated antigens. With the composition, vaccination processes are significantly simplified, and the vaccination efficiency is improved with reduced costs.

The invention discloses a human vaccine for preventing hydrophobia and tetanus, which belongs to the field of vaccines. The vaccine consists of a hydrophobia vaccine and a tetanus toxin, wherein the hydrophobia vaccine is obtained by inoculating a CDKHBP-1 strain onto a human diploid cell WI-38 and purifying. By using the hydrophobia vaccine and the tetanus toxin prepared with the preparation method disclosed by the invention together, immunity to hydrophobia and tetanus can be realized; and moreover, the tetanus toxin can be used for remarkably enhancing valence effect of the hydrophobia vaccine, plays a role in enhancing immunity, and is convenient for administration.

The invention provides rabies vaccine for human being. The vaccine comprises an outer membrane segment of cracked rabies complete viral particles and tetanus toxoid, and the outer membrane segment comprises spike and matrix protein. Each dose of the rabies vaccine comprises 10 to 100 micrograms of viral protein; the dosage of the tetanus toxoid is 2 Lf/dose to 10 Lf/dose; and the dosage of aluminum phosphate adjuvant is 0.5mg/dose. Compared with the existing virus purified stock solution, the rabies vaccine for human being has the advantages that the content of impurity protein is greatly reduced, the immunogenicity and the potency are high, and the rabies vaccine is safer to use.

The present invention discloses a method for producing a tetanus toxoid raw liquid through a chromatography purification method, and belongs to the technical field of biology. The production method comprises: filtering a bacillus tetani culture solution, carrying out ultrafiltration concentration on the filtrate through a 30 KD ultrafiltration membrane to achieve 1/20-1/10 of the original volume, washing the concentrated solution, collecting, and carrying out ion exchange chromatography, hydrophobic chromatography, primary membrane filtration, detoxification, ultrafiltration and secondary membrane filtration on the concentrated solution to obtain the tetanus toxoid raw liquid. The method of the present invention has advantages of simple process, easy operation, high production efficiency and low cost. The tetanus toxoid raw liquid produced by the method of the present invention has advantages of single tetanus toxoid component and high purity so as to obtain the good immunogenicity and reducing the occurrence of adverse events following immunization.

The invention relates to the filed of pharmaceutical preparation, in particular to single dose immunization against tetanus toxin cation dextran microspheres and a preparation method thereof. The single dose immunization against tetanus toxin cation dextran microspheres are prepared by carrying tetanus toxin after electrostatic interaction on cation hydroxyethyl acrylate dextran microspheres. The tetanus toxin controlled release microspheres can reduce the injection frequency of tetanus vaccine, improve the vaccination coverage and reduce the drop-out rate, thereby effectively preventing tetanus and providing a single dose tetanus toxin controlled release vaccine preparation with long-term effect and realizing the whole course immunity by one injection.

The invention provides a fully humanized anti-tetanus bispecific antibody. The bispecific antibody includes a single-stranded unit A and a single-stranded unit B, both the single-stranded units A andB contain a single-stranded variable fragment (scFv), a human IgG1 hinge region and an Fc fragment, wherein the scFv of the single-stranded unit A has specific binding ability to a region centered onTrp 1289 of tetanus toxoid, and the scFv of the single-stranded unit B has specific binding ability to a region centered on Arg1216 of the tetanus toxoid. The invention also provides a construction method and application of the bispecific antibody. After neutralization experiments in mice, results show that the antibody has a neutralizing protection effect, and the bispecific antibody can be usedas a diagnostic reagent to detect the quality of a tetanus toxoid antigen, and can replace the tetanus antitoxin, equine tetanus immunoglobulin or human tetanus immunoglobulin to be used for passive immunization.

The invention relates to a tetanus toxoid monoclonal antibody and application thereof, and belongs to the field of immunology. Mouse spleen cells and mouse myeloma cells are fused with one another after mice are subjected to tetanus toxoid immunization, tetanus-toxoid-resistant specific monoclonal antibody hybridoma cell strains can be generated by means of screening, and a preservation number of the hybridoma cell strains is CGMCC No.10590. The tetanus toxoid monoclonal antibody and the application have the advantages that the potency of the monoclonal antibody secreted by the hybridoma cell strains can reach 10<7>, an affinity constant of the monoclonal antibody is 1.24*10<9>M<-1>, and the tetanus toxoid monoclonal antibody can be used for preparing tetanus toxoid antigen detection reagent kits, also can be applied to detecting tetanus vaccine production procedures by the aid of enzyme-linked immunosorbent assay and detecting the content of toxoid in finished vaccine and has a broad application prospect and high market value.

The invention discloses a haemophilus influenzae type b (Hib) polysaccharide and refined tetanus toxoid coupling process which includes steps of Hib polysaccharide-AH derivant generation and Hib polysaccharide-tetanus toxoid (TT) combination preparation. The Hib polysaccharide-AH derivant generation includes steps of A1, polysaccharide dissolving, A2, polysaccharide activation, A3, antidiuretic hormone addition for connection and A4, CNBr and antidiuretic hormone (ADH) removing. The Hib polysaccharide-TT combination preparation includes the following steps: B1, adding TT solution, B2, adding carbodiimide (EDAC), B3, removing the EDAC to obtain polysaccharide-TT carbodiimide; and B4, separating and pourifying the polysaccharide-TT carbodiimide, eluting, degerming and filtering to obtain the polysaccharide-TT combination. The Hib polysaccharide and refined tetanus toxoid coupling process has the advantages of improving working efficiency, saving time and labor and simultaneously saving using amount of NaCl solution and reduces the contaminated rate of samples compared with dialysis adopted by the traditional process.

The invention relates to a method for preparing group A meningococcal capsular polysaccharide conjugate vaccine. The method includes the following steps that group A meningococcal capsular polysaccharide is diluted, activated and coupled into a group A meningococcal polysaccharide-sebacic dihydrazide derivative together with sebacic dihydrazide; then the group A meningococcal polysaccharide-sebacic dihydrazide derivative and a tetanus toxoid solution are subjected to a catalytic reaction through carbodiimide, so that group A meningococcal capsular polysaccharide and carrier protein conjugate is obtained. According to the method, the sebacic dihydrazide is used as a coupling agent in the preparation process of the group A meningococcal conjugate vaccine; compared with adipic dihydrazide, the sebacic dihydrazide has two more methylenes on carbon chains, molecular chains are longer, the steric hindrance of biomacromolecules can be better resisted, and the conjugation yield is increased.

The invention discloses an acellular pertussis combined vaccine and a preparation method thereof and belongs to the technical field of production and preparation of vaccines. The acellular pertussis combined vaccine is prepared from the following raw material components: 5-40Mu g of pertussis toxin, 5-40Mu g of filamentous hemagglutinin, 2-10Mu g of pertussis adhesin, 10-25lf of diphtheria toxoid, 4-10lf of tetanus toxoid, 1.0-2.0mg/ml of aluminium hydroxide and 7.5-9.5g/L of sodium chloride. The preparation method of the acellular pertussis combined vaccine comprises the following steps: preparing monovalent vaccine original fluids, mixing and diluting. The acellular pertussis combined vaccine is clear and definite in ingredients, quality control can be easily realized, the side effect is small, and the safety is high; and the preparation method of the acellular pertussis combined vaccine is simple to operate, convenient in preparation and low in cost, so that the acellular pertussis combined vaccine is applicable to industrial mass production.

The invention provides combined vaccine for adsorbing Diphtheria, tetanus and acellular pertussis-Sabin (DTaP-sIPV) inactivated poliovirus and preparation thereof. The DTaP-sIPV is characterized in that each 100ml of the combined vaccine comprises the following components: 400-1800ug (PN) of acellular pertussis (AP) stock solution, 300-700Lf of tetanus toxoid (TT), 1000-2500Lf of diphtheria toxoid (DT), 126-154mg of Al(OH)<3>, 3000-6000DU of sIPV I, 5700-7100DU of sIPV II, 4500-9000DU of sIPV III, 765-935mg of NaCl, 0-600mg of 2-phenoxyethanol and the balance of H<2>O. Compared with the existing products, the DTaP-sIPV has the advantages of higher biological safety, better side reaction and the like; and the DTaP-sIPV has the beneficial effects of preventing a plurality of target diseases, reducing inoculating needles, simplifying immunization programs, improving inoculation rate, reducing opportunity of cross infection, being popular with a majority of parents and children, saving various expenses and facilitating smooth promotion of immunization plan.